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Dear	Editor,
Psoriasis	is	a	chronic,	inflammatory	disease	that	affects	the	skin	
and	joints.	It	has	a	prevalence	of	2-3%	of	the	world’s	population.1 It has 
a multifactorial etiology with genetic and environmental factors lead-
ing	to	immunological	dysfunction	and	characteristic	inflammation.1
Helicobacter pylori (H. pylori)	is	a	gram-negative,	microaero-
philic,	spiral	shaped,	mobile	bacterium	with	worldwide	diffusion.	
Although	it	is	well	known	that H. pylori is the main cause of peptic 
ulcer,	an	association	between	this	infection	and	several	extragastric	
manifestations	has	been	reported	in	the	latest	two	decades,	which	
include	 cardiovascular,	 liver,	 skin,	 rheumatologic	 diseases,	 and	
blood disorders.
In	 a	 recent	 interesting	 prospective	 study,	 Mesquita	 et al. 
found a higher seroprevalence of H. pylori infection in psoriatic pa-
tients	(72.1%)	than	in	controls	(33.3%)	(P=0.002).2	Furthermore,	they	
found a higher seroprevalence among patients with severe psoriasis 
(79%)	compared	with	those	with	moderate	(69.5%)	or	mild	(46.2%)	
disease	(P=0.045).	Both	cases	and	controls	did	not	suffer	from	gas-
trointestinal symptoms and had a similar socioeconomic level.
 These results are in contrast with those of two studies in 
which H. pylori infection was searched with a method able to detect 
the	active	infection	and	not	the	potential	contact	during	life.	Fabrizi	
et al., who	used	the	urea	breath	test	(UBT),	concluded	that	there	is	
a low prevalence of H. pylori infection in psoriatic children and ad-
olescents,	a	similar	result	found	in	children	without	skin	diseases.3 
Onsun et al., using	the	stool	test,	found	a	prevalence	of H. pylori in-
fection	of	61.3%	in	patients	with	psoriasis	versus	59.3%	in	the	control	
group	(P>0.05).4
	 To	explain	these	different	results,	 it	 is	crucial	to	analyze	
the	potential	 selection	biases.	 In	particular,	 a	wide	and	well-char-
acterized	 control	group	 is	 a	key	 step	 in	planning	and	conducting	
a study. The control group is used to compare the history of expo-
sure in the cases with that in individuals who are free of the study 
disease. Individuals selected as controls should not only be free of 
the	study	disease,	but	also	be	similar	to	the	cases	concerning	past	
potential for exposure.
In	the	study	of	Mesquita	et al.,	the	sample	size	of	the	control	
group	was	 small	 (21	patients).2	 Furthermore,	 the	method	used	 to	
detect H. pylori infection could have led to misinterpreted data. UBT 
and stool test are direct tests with higher accuracy than serology 
to diagnose the presence of the bacterium. Serum positivity for H. 
pylori	antigens	is	a	marker	of	exposure	and	not	necessarily	of	“true	
infection”,	revealing	some	drawbacks.	The	most	important	signal	is	
its	marked	variability	in	accuracy	with	the	possible	interpretation	of	
positivity	as	consequence	of	active	infection	as	well	as	of	previous	
bacterial exposure.5
For	these	reasons,	only	validated	serological	kits	to	test	for	
active H. pylori infections should be used and a wider control group 
should	be	considered	by	future	studies	to	confirm	our	findings.	q
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